Teva Pharmaceuticals Industries Ltd. has appointed Angus Grant as executive vice president, business development, effective August 1. Grant will be based out of Teva’s U.S. headquarters in Parsippany, NJ.

Grant joins Teva with more than 25 years of experience in the global pharmaceutical and biotech industry, across a variety of fields including business development, R&D and regulatory affairs. Most recently, Grant served as the chief business executive at BeiGene, overseeing business development, clinical and business insights and valuation, investments and collaborations, and alliance management.

Prior to BeiGene, Grant served as CEO of the Dementia Discovery Fund, a specialist venture capital fund focused on therapeutics for age-related dementias and neurodegenerative disease. Earlier in his career, Grant spent 12 years at Celgene, serving in various leadership roles including corporate vice president of business development, and vice president, regulatory affairs.

Richard Francis, Teva’s President, and CEO said: “We are pleased to welcome a leader of Angus caliber to our executive team at Teva. With a distinguished career spanning over more than two and a half decades in the global pharmaceutical and biotech industry, his breadth of experience and demonstrated expertise in business development, innovative R&D, and scientific affairs will be a significant asset to our organization.

Grant said, “I am thrilled to be joining Teva’s executive leadership team and am inspired by Teva’s purpose and strategy to drive growth by stepping up and leaning more into innovation. I am looking forward to work with the extended Teva team and leading the excellent business development team, to drive innovation and to partner with the best minds in academia and the industry to bring meaningful impact and value for patients worldwide and for Teva.”